Guardant Health (NASDAQ:GH) Price Target Raised to $125.00

Guardant Health (NASDAQ:GH) had its target price upped by Wells Fargo & Company from $120.00 to $125.00 in a research report report published on Friday,Benzinga reports. They currently have an overweight rating on the stock.

Several other research analysts have also recently issued reports on GH. UBS Group reissued a “buy” rating and issued a $175.00 price target on shares of Guardant Health in a research note on Friday, January 30th. Leerink Partners increased their target price on shares of Guardant Health from $115.00 to $155.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. Stifel Nicolaus raised their target price on shares of Guardant Health from $120.00 to $130.00 and gave the company a “buy” rating in a research note on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research note on Thursday, January 22nd. Finally, Barclays reiterated an “overweight” rating and set a $130.00 price objective on shares of Guardant Health in a research note on Friday. Twenty-one research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $117.43.

Guardant Health Trading Down 3.1%

Shares of NASDAQ:GH opened at $103.10 on Friday. The firm’s 50 day moving average is $106.69 and its two-hundred day moving average is $86.51. The firm has a market capitalization of $13.52 billion, a P/E ratio of -31.15 and a beta of 1.63. Guardant Health has a 52 week low of $34.88 and a 52 week high of $120.74.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The firm had revenue of $281.27 million during the quarter, compared to analyst estimates of $269.74 million. During the same period in the previous year, the company posted ($0.62) EPS. The company’s revenue for the quarter was up 39.4% on a year-over-year basis. Analysts predict that Guardant Health will post -2.9 EPS for the current year.

Insider Buying and Selling at Guardant Health

In related news, insider Terilyn J. Monroe sold 8,571 shares of the firm’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $114.09, for a total transaction of $977,865.39. Following the completion of the sale, the insider directly owned 20,990 shares in the company, valued at approximately $2,394,749.10. This trade represents a 28.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Amirali Talasaz sold 100,000 shares of Guardant Health stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $105.05, for a total transaction of $10,505,000.00. Following the completion of the transaction, the chief executive officer owned 168,223 shares in the company, valued at approximately $17,671,826.15. This trade represents a 37.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 434,511 shares of company stock valued at $45,580,887. Corporate insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Guardant Health

Institutional investors and hedge funds have recently modified their holdings of the stock. V Square Quantitative Management LLC purchased a new stake in shares of Guardant Health during the fourth quarter valued at $27,000. Chesapeake Asset Management LLC purchased a new position in Guardant Health in the 4th quarter worth about $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Guardant Health during the 4th quarter worth about $31,000. Elyxium Wealth LLC purchased a new stake in Guardant Health during the fourth quarter valued at about $35,000. Finally, Parallel Advisors LLC boosted its holdings in shares of Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after buying an additional 219 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Guardant Health News Summary

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Multiple brokerages raised price targets and maintained buy/overweight ratings (Leerink to $180, JPMorgan to $130, Wells Fargo to $125, BTIG to $145, Canaccord to $135), signaling analyst confidence in upside from current levels. Analyst Raises Coverage
• Positive Sentiment: Q4 revenue beat and strong growth: Guardant reported $281.3M in Q4 revenue, +39% YoY and above consensus; management issued FY2026 revenue guidance around $1.3B, above Street expectations — a growth signal for core oncology testing. Press Release
• Positive Sentiment: Research coverage expansion: Robert W. Baird initiated coverage, which can broaden institutional interest and trading liquidity. Coverage Start
• Neutral Sentiment: Conference call and transcript available — provides detail on cadence of test volume, reimbursement progress and product roadmap; useful for digging into guidance assumptions. Earnings Transcript
• Neutral Sentiment: Market materials (slide deck, press release) posted for investors to verify segment trends and margin assumptions. Slide Deck / Press Release
• Neutral Sentiment: Short-interest data flagged a “significant increase” entry but shows 0 shares / NaN in the feed — the published data appears inconsistent, so short-interest impact is unclear. Short Interest Note
• Negative Sentiment: EPS miss: GAAP loss of ($0.50) vs. consensus (~($0.43)), which disappointed some investors despite revenue upside and may have pressured the stock near the close. Earnings Reaction
• Negative Sentiment: Management left EPS guidance effectively blank in the release (revenue guidance given but no numeric EPS target), which can create uncertainty around near-term profitability expectations. Guidance Details

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.